# US 2001/0025196 A1 · Prosthetic heart valve with surface modification

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0025196 A1
- Document ID: US20010025196A1
- Status: Published application
- Kind: A1
- Application number: 09/746,979
- Filed: 2000-12-21
- Published: 2001-09-27
- Earliest claimed: 1996-09-06
- Assignees: Carbomedics, Inc.
- Inventors: Joseph Andrew Chinn; Jack R. Frautschi; Richard E. Phillips JR.
- Web page: https://patentgrep.com/patent/US20010025196A1

## CPC

- A61L 27/34: Macromolecular materials
- A61L 27/28: Materials for coating prostheses
- A61F 2/2412: {with soft flexible valve members, e.g. tissue valves shaped like natural valves}
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)

## Abstract

Biocompatible prostheses, specifically, biocompatible heart valves, are described having incorporated therein an effective amount of coating applied thereto to render the valve resistant to in vivo pathologic thrombus formation and in vivo pathologic mineralization. Preferably, the coating is derived from a precursor having the formula: X-Y-Z wherein X is a chemically reactive group capable, upon activation, of bonding to the surface of the heart valve; Y is either null or a relatively inert skeletal moiety resistant to cleavage in aqueous physiological fluids; and Z is a functionally active moiety or a biocompatible agent.

## Claims

### Claim 1

A method for reducing mineralization and thrombus formation in a biocompatible polymeric heart valve after implantation, comprising:
coating, prior to implantation, at least a portion of the heart valve with a coating precursor of the formula:
X-Y-Z
wherein X is a chemically reactive group capable, upon activation, of bonding to the surface of the heart valve; Y is either null or a relatively inert skeletal moiety resistant to cleavage in aqueous physiological fluids; and Z is a functionally active moiety or a biocompatible agent; and
bonding the precursor to at least a portion of the heart valve, to produce a heart valve with a bonded coating;
wherein the bonded coating is present in an amount effective to reduce mineralization and thrombus formation after implantation.

### Claim 2 (depends on 1)

The method of claim 1, wherein X is a photochemically reactive group.

### Claim 3 (depends on 2)

The method of claim 2, wherein X is derived from a compound selected from aryl azides, alkyl azides, acyl azides, azidoformates, sulfonylazides, phosphoryl azides, diazo compounds, diazirines, ketenes, or aromatic ketones.

### Claim 4 (depends on 1)

The method of claim 1, wherein Y is derived from a compound selected from C1-C10 alkyldiol or diamine; polyethyleneoxide (PEO); amino-substituted PEO (MW=200−1450); diamine-terminated PEO (MW=200−1450); ε-amino caproic acid (EAC); ethylene diamine (ED); or diaminopropane (DAP).

### Claim 5 (depends on 1)

The method of claim 1, wherein Z is derived from a compound selected from functionalized C1-C18 alkylene, functionalized mucopolysaccharides, functionalized polyoxyethylene, functionalized vinyl polymers, or functionalized polypeptides.

### Claim 6 (depends on 1)

The method of claim 1, wherein X is derived from a substituted benzyl benzoyl having structure I: 4
wherein R1 is a carboxyl group;
Y is derived from diaminopropane (DAP) or a diamine-terminated amide; and,
Z is derived from a compound selected from functionalized fatty acids, functionalized hyaluronic acid, functionalized polyoxyethylene, functionalized heparin, or functionalized polyvinylpyrrolidone.

### Claim 7 (depends on 6)

The method of claim 6, wherein the precursor has the structure II or III: 5

### Claim 8

A biocompatible heart valve, comprising:
a stent defining a blood flow path; and
a plurality of polymeric leaflets having applied thereto a surface coating effective to render the heart valve resistant to in vivo pathologic thrombus formation and in vivo pathologic mineralization, wherein the surface coating comprises a fatty acid moiety, a hyaluronic acid moiety, a polyoxyethylene moiety, a heparin moiety, or a vinylpyrrolidone moiety.

### Claim 9 (depends on 8)

The biocompatible heart valve of claim 8, wherein the polymeric leaflets comprise a polymer selected from siloxane polymers, polydimethylsiloxanes, silicone rubber, polyurethane, polyether urethane, polyester urethane, polyamide, polycarbonate, polyester, polypropylene, polyethylene, polystyrene, polyvinyl chloride, polytetrafluoroethylene, polysulfone, cellulose acetate, polymethylmethacrylate, or poly(ethylene/vinylacetate).

### Claim 10 (depends on 9)

The biocompatible heart valve of claim 9, wherein the polymer is selected from silicone rubber, polyurethane, polyetherurethane, polyetherurethane/polysiliconeurethane, or epoxy-bisphosphonate-modified polyetherurethane.

### Claim 11 (depends on 8)

The biocompatible heart valve of claim 8, wherein the surface coating comprises a benzyl benzoyl moiety bonding the surface coating to the polymeric leaflets.

### Claim 12 (depends on 8)

The biocompatible heart valve of claim 8, wherein the coating is covalently bonded to the polymeric leaflets.

### Claim 13 (depends on 8)

The biocompatible heart valve of claim 8, wherein the coating is non-covalently bonded to the polymeric leaflets.

### Claim 14 (depends on 8)

The biocompatible heart valve of claim 8, wherein the surface coating is derived from a precursor of the formula:
X-Y-Z
wherein X is a chemically reactive group capable, upon activation, of bonding to the surface of the heart valve; Y is either null or a relatively inert skeletal moiety resistant to cleavage in aqueous physiological fluids; and Z is a fatty acid moiety, a hyaluronic acid moiety, a polyoxyethylene moiety, a heparin moiety, or a vinylpyrrolidone moiety.

### Claim 15 (depends on 14)

The biocompatible heart valve of claim 14, wherein X is a photochemically reactive group.

### Claim 16 (depends on 15)

The biocompatible heart valve of claim 15, wherein X is derived from a compound selected from aryl azides, alkyl azides, acyl azides, azidoformates, sulfonylazides, phosphoryl azides, diazo compounds, diazirines, ketenes, or aromatic ketones.

### Claim 17 (depends on 14)

The biocompatible heart valve of claim 14, wherein Y is derived from a compound selected from C1-C10 alkyldiol or diamine; polyethyleneoxide (PEO); amino-substituted PEO (MW=200−1450); diamine-terminated PEO (MW=200−1450); ε-amino caproic acid (EAC); ethylene diamine (ED); or diaminopropane (DAP).

### Claim 18 (depends on 16)

The biocompatible heart valve of claim 16, wherein X is derived from a substituted benzyl benzoyl having structure I: 6
wherein R1 is a carboxyl group;
Y is derived from diaminopropane (DAP) or a diamine-terminated amide; and,
Z is derived from a compound selected from functionalized fatty acids, functionalized hyaluronic acid, functionalized polyoxyethylene, functionalized heparin, or functionalized vinylpyrrolidone.

### Claim 19 (depends on 18)

The method of claim 18, wherein the precursor has the structure II or III: 7
